Bionovo Initiates Menerba (MF101) Phase 3 Clinical Trial For Menopausal Hot Flashes

Bionovo, Inc. (Nasdaq: BNVI), a pharmaceutical company focused on the discovery and development of safe and effective treatments for women’s health and cancer, announced that enrollment has started to the Phase 3 pivotal clinical trial evaluating the safety and efficacy of two doses of Menerba™ (MF101) among a cohort of postmenopausal women for the treatment of menopausal hot flashes…

Bionovo Announces Enrollment Started In The Menerba (MF101) Phase 1 "Tolerability" Clinical Trial For Menopausal Hot Flushes

Bionovo, Inc…

FDA Approves Bionovo's Clinical Development Plan For Menerba

Bionovo, Inc. (Nasdaq: BNVI), a pharmaceutical company focused on the discovery and development of safe and effective treatments for women’s health and cancer, announced that the U.S. Food and Drug Administration (FDA) has approved the company’s total clinical development plan for Menerba, the company’s drug candidate for menopausal hot flashes…

FDA Approves Manufacturing Plan For Menerba, Bionovo's Menopausal Hot Flash Drug Candidate

Bionovo, Inc. (Nasdaq: BNVI, BNVID) announced that the U.S. Food and Drug Administration (FDA) accepted the Company’s Chemistry, Manufacturing and Controls (CMC) plan for its lead drug candidate, Menerba®, in a Type “B” or “End of Phase 2″ meeting. With this designation, the decisions and agreements are now considered binding on the Company and the FDA…

FDA Approves Manufacturing Plan For Menerba, Bionovo's Menopausal Hot Flash Drug Candidate

Bionovo, Inc. (Nasdaq: BNVI, BNVID) announced that the U.S. Food and Drug Administration (FDA) accepted the Company’s Chemistry, Manufacturing and Controls (CMC) plan for its lead drug candidate, Menerba®, in a Type “B” or “End of Phase 2″ meeting. With this designation, the decisions and agreements are now considered binding on the Company and the FDA…

Next Page »